Gainor, J. F., Schneider, J. G., Gutierrez, M., Orcutt, J. M., Finley, G. G., Otterson, G. A., … Borghaei, H. (2020). Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Gainor, Justin F., Jeffrey Gary Schneider, Martin Gutierrez, James Michael Orcutt, Gene Grant Finley, Gregory Alan Otterson, Igor I. Rybkin, et al. “Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Gainor JF, Schneider JG, Gutierrez M, Orcutt JM, Finley GG, Otterson GA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Gainor, Justin F., et al. “Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Gainor JF, Schneider JG, Gutierrez M, Orcutt JM, Finley GG, Otterson GA, Rybkin II, Reddy PS, Horn L, Brahmer JR, Bastos BR, Awad MM, Hellmann MD, Ramalingam SS, Ready NE, Spigel DR, Kasinathan RS, Dorange C, Borghaei H. Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2. JOURNAL OF CLINICAL ONCOLOGY. 2020.